Verapamil
Verapamil, Verelan (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Isoptin on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 10, sodium leak channel NALCN, voltage-dependent L-type calcium channel subunit alpha-1D, voltage-gated potassium channel KCNC2, cytochrome P450 3A4, voltage-dependent L-type calcium channel subunit alpha-1F, two pore channel protein 1, two pore channel protein 2, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Verapamil, Verelan (discontinued: Calan, Covera, Isoptin, Verapamil)
CombinationsTrandolapril verapamil (discontinued: Tarka)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trandolapril
+
Verapamil hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amazing face | OTC monograph final | 2010-05-11 |
| amazonian clay 12-hour full coverage foundation broad spectrum spf 15 sunscreen | OTC monograph not final | 2020-12-17 |
| bye bye foundation full coverage moisturizer spf 50 | OTC monograph not final | 2019-12-30 |
| continuous coverage makeup | OTC monograph not final | 2011-12-19 |
| dermablend professional cc continuous correction full coverage makeup broad spectrum spf 50 plus sunscreen | C200263 | 2023-12-27 |
| dermablend professional smooth camo medium coverage foundation broad spectrum spf 25 sunscreen | C200263 | 2023-12-27 |
| dermaquest tm skin therapy, breathable coverage tm mineral foundation spf-30, dermaminerals tm | OTC monograph not final | 2011-02-23 |
| double duty beauty shape tape cloud coverage broad spectrum spf 15 sunscreen | C200263 | 2023-12-21 |
| esika | OTC monograph not final | 2011-09-20 |
| esika perfect skin coverage concealer spf 17 | OTC monograph final | 2014-04-08 |
Show 59 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08D: Selective calcium channel blockers with direct cardiac effects
— C08DA: Phenylalkylamine derivatives, selective calcium channel blockers with direct cardiac effects
— C08DA01: Verapamil
— C08DA51: Verapamil, combinations
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB10: Trandolapril and verapamil
HCPCS
No data
Clinical
Clinical Trials
181 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 2 | 7 | 6 | 17 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 5 | 4 | 5 | 16 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 4 | 1 | 3 | 4 | 12 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 3 | 1 | 6 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 2 | 2 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | 2 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 1 | 1 | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | 3 | 4 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | 3 | 4 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | 1 | 1 | — | 2 | — | 4 |
Show 47 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Phenylketonurias | D010661 | — | E70.0 | — | 1 | 6 | — | 3 | 10 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 3 | 1 | — | 1 | 6 |
| Ischemic stroke | D000083242 | — | — | 4 | 1 | 1 | — | — | 5 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | 2 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 1 | 1 | — | — | 3 |
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | 1 | 2 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | 1 | 1 | — | — | 1 |
| Hemostatic disorders | D020141 | — | — | — | 1 | 1 | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | — | — | 1 |
| Body-weight trajectory | D000077962 | — | — | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 18 | 1 | — | — | 1 | 19 |
| Thrombosis | D013927 | — | — | — | 1 | — | — | 4 | 5 |
| Pharmacokinetics | D010599 | — | — | 2 | 1 | — | — | — | 3 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | 2 | 3 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 1 | — | — | 1 | 2 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | 1 | 1 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Ischemia | D007511 | EFO_0000556 | — | 3 | — | — | — | — | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | — | — | — | — | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | — | — | — | 1 | 2 |
| Nasal polyps | D009298 | HP_0100582 | J33 | 1 | — | — | — | 1 | 2 |
| Rhinosinusitis | D000096825 | — | — | 1 | — | — | — | 1 | 2 |
| Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | — | 1 |
| Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Show 32 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 3 | 3 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 3 | 3 |
| No-reflow phenomenon | D054318 | — | — | — | — | — | — | 2 | 2 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 2 | 2 |
| Coronary restenosis | D023903 | EFO_0004224 | — | — | — | — | — | 2 | 2 |
| Angioplasty | D017130 | — | — | — | — | — | — | 1 | 1 |
| Coronary angiography | D017023 | — | — | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Hemangioendothelioma | D006390 | — | — | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Verapamil |
| INN | verapamil |
| Description | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile. |
| Classification | Small molecule |
| Drug class | coronary vasodilators (verapamil type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 52-53-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL6966 |
| ChEBI ID | 77733 |
| PubChem CID | 2520 |
| DrugBank | DB00661 |
| UNII ID | CJ0O37KU29 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNC2
KCNC2
Organism
Homo sapiens
Gene name
KCNC2
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily C member 2
Protein synonyms
potassium channel, voltage gated Shaw related subfamily C, member 2, potassium voltage-gated channel, Shaw-related subfamily, member 2, Shaw-like potassium channel, Voltage-gated potassium channel Kv3.2
Uniprot ID
Mouse ortholog
Kcnc2 (268345)
potassium voltage-gated channel subfamily C member 2 (Q14B80)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Verelan – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Verapamil
+
Trandolapril
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Verapamil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,571 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tarka, Trandolapril and verapamil hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,428 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use